Extensively drug-resistant tuberculosis: Early access to bedaquiline for a UK patient

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 292-294

  Van Halsema, Clare ^a   Humphreys, Susan ^a   Bonington, Alec ^a,b  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; AMYLASE; AZITHROMYCIN; BEDAQUILINE; CAPREOMYCIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; THYROXINE;

ABSENCE OF SIDE EFFECTS; ADULT; ASYMPTOMATIC INFECTION; CASE REPORT; COMPASSIONATE USE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FEVER; HUMAN; HYPOTHYROIDISM; INTERFERON GAMMA RELEASE ASSAY; LETTER; LUNG NODULE; MEDIASTINUM LYMPHADENOPATHY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; UNITED KINGDOM;

ADULT; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; EMIGRANTS AND IMMIGRANTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GREAT BRITAIN; HUMANS; INDIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891918791     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00128613     Document Type: Letter

References (10)

1. Health Protection Agency. Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2012. London, Health Protection Agency, 2012.
2. World Health Organization. Anti-tuberculosis drug resistance in the world. Report No. 4. Geneva, WHO, 2008.
3. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, WHO, 2013.
4. National Institute for Health and Clinical Excellence. Clinical diagnosis and management of tuberculosis and measures for its prevention and control. NICE clinical guideline 117. London, NICE, 2011.
5. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
6. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: Individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
7. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolierability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
8. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
9. Migliori GB, Zellweger I, Abubakar E, et al. European union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
10. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: The ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.